-
1
-
2
-
3
-
4
Rechargeable Li/Cl2 Battery Down to −80 °C
Veröffentlicht in Advanced materials (Weinheim)
VolltextArtikel -
5
-
6
Stem cells in cancer therapy: opportunities and challenges
Veröffentlicht in Oncotarget
VolltextArtikel -
7
-
8
-
9
Multifunctional two-dimensional nanocomposites for photothermal-based combined cancer therapy
Veröffentlicht in Nanoscale
VolltextArtikel -
10
Pharmacological properties of baicalin on liver diseases: a narrative review
Veröffentlicht in Pharmacological reports
VolltextArtikel -
11
Diagnostic and prognostic nomograms for bone metastasis in hepatocellular carcinoma
Veröffentlicht in BMC cancer
VolltextArtikel -
12
-
13
Reply to Alessia Cimadamore, Liang Cheng, Antonio Lopez-Beltran, Marina Scarpelli, and Rodolfo Montironi’s Letter to the Editor re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.009: Focus on Intraductal Carcinoma of the Prostate
Veröffentlicht in European urology
VolltextArtikel -
14
-
15
-
16
Re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Systems in Combination Provides Valuable Information for Establishing Prognostic Risk Groups. Eur Urol 2021;79:489–91
Veröffentlicht in European urology
VolltextArtikel -
17
-
18
-
19
Reply to Alessia Cimadamore, Marina Scarpelli, Liang Cheng, et al’s Letter to the Editor, re: Maria Chiara Sighinolfi, Bernardo Rocco’s Words of Wisdom re: EAU Guidelines: Prostate Cancer 2019. Mottet N, van den Bergh RCN, Briers E, et al. https://uroweb.org/guideline/prostate-Cancer/. Eur Urol 2019, 76:871
Veröffentlicht in European urology
VolltextArtikel -
20
Reply to Alessia Cimadamore, Liang Cheng, Marina Scarpelli, et al’s Letter to the Editor re: Alfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti–PD-1/PD-L1 in Advanced Urothelial Cancer. Eur Urol 2020;77:269–76. Progression and Hyperprogression Versus Pseudoprogression: Morphologic Documentation
Veröffentlicht in European urology
VolltextArtikel